Stay updated on Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page
- Check4 days agoChange DetectedThe record history now shows the latest revision (v3.5.4) as the current version, replacing the earlier v3.5.3 entry.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedThe page revision/version label was updated from v3.5.2 to v3.5.3, reflecting a site or interface version change rather than any update to the clinical trial record itself.SummaryDifference0.1%

- Check32 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision v3.5.0 was added to the record history and Revision v3.4.3 was removed.SummaryDifference0.1%

- Check68 days agoChange DetectedRevision history updated: added v3.4.3 and removed v3.4.2.SummaryDifference0.1%

- Check96 days agoChange DetectedAdded Revision: v3.4.2 to the history; deletions remove a government-funding notice and the older Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.